You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
35 Items
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
bendamustine (PDRP prior authorization),
cytarabine,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Chronic Lymphocytic Leukemia
... Show more tags
Drugs Used:
bendamustine
... Show more tags
Quick Link(s):
Regimen Monograph
Apr 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Drugs Used:
bendamustine (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2017
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
... Show more tags
Drugs Used:
oBINutuzumab,
bendamustine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
... Show more tags
Drugs Used:
riTUXimab,
bendamustine,
riTUXimab (subcut)
... Show more tags
Quick Link(s):
Regimen Monograph
Feb 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Drugs Used:
riTUXimab (Unfunded),
bendamustine (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Oct 2017
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
capecitabine,
temozolomide (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - Previously Untreated Chronic Lymphocytic Leukemia
ODB - General Benefit
    chlorambucil
... Show more tags
Drugs Used:
chlorambucil,
oBINutuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
... Show more tags
Drugs Used:
oBINutuzumab,
chlorambucil
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2018
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
... Show more tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    cyclophosphamide - oral tablets
... Show more tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
... Show more tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019